Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.82
AFFX's Cash to Debt is ranked higher than
58% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. AFFX: 0.82 )
AFFX' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: 0.82

Equity to Asset 0.60
AFFX's Equity to Asset is ranked higher than
67% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. AFFX: 0.60 )
AFFX' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.95
Current: 0.6

0.19
0.95
Interest Coverage 0.33
AFFX's Interest Coverage is ranked lower than
59% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 178.70 vs. AFFX: 0.33 )
AFFX' s 10-Year Interest Coverage Range
Min: 0.27   Max: 37.16
Current: 0.33

0.27
37.16
F-Score: 8
Z-Score: 2.59
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.12
AFFX's Operating margin (%) is ranked higher than
77% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.24 vs. AFFX: 5.12 )
AFFX' s 10-Year Operating margin (%) Range
Min: -139.9   Max: 17.26
Current: 5.12

-139.9
17.26
Net-margin (%) 3.11
AFFX's Net-margin (%) is ranked higher than
77% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. AFFX: 3.11 )
AFFX' s 10-Year Net-margin (%) Range
Min: -113.64   Max: 17.9
Current: 3.11

-113.64
17.9
ROE (%) 4.00
AFFX's ROE (%) is ranked higher than
75% of the 272 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. AFFX: 4.00 )
AFFX' s 10-Year ROE (%) Range
Min: -68.27   Max: 22.99
Current: 4

-68.27
22.99
ROA (%) 2.25
AFFX's ROA (%) is ranked higher than
77% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. AFFX: 2.25 )
AFFX' s 10-Year ROA (%) Range
Min: -33.34   Max: 10.32
Current: 2.25

-33.34
10.32
ROC (Joel Greenblatt) (%) 25.70
AFFX's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. AFFX: 25.70 )
AFFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -128.18   Max: 80.9
Current: 25.7

-128.18
80.9
Revenue Growth (3Y)(%) 8.20
AFFX's Revenue Growth (3Y)(%) is ranked higher than
80% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. AFFX: 8.20 )
AFFX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -33.6   Max: 102.9
Current: 8.2

-33.6
102.9
EBITDA Growth (3Y)(%) 52.40
AFFX's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. AFFX: 52.40 )
AFFX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -24.4   Max: 52.4
Current: 52.4

-24.4
52.4
EPS Growth (3Y)(%) -50.00
AFFX's EPS Growth (3Y)(%) is ranked higher than
54% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. AFFX: -50.00 )
AFFX' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3   Max: 25.1
Current: -50

-55.3
25.1
» AFFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AFFX Guru Trades in Q1 2014

Joel Greenblatt 151,285 sh (+385.09%)
Paul Tudor Jones 56,400 sh (+15.87%)
PRIMECAP Management 10,690,540 sh (+0.22%)
Murray Stahl 104,000 sh (unchged)
Jim Simons 769,223 sh (-25.50%)
Chuck Royce 90,000 sh (-30.77%)
» More
Q2 2014

AFFX Guru Trades in Q2 2014

Murray Stahl 104,000 sh (unchged)
Chuck Royce 90,000 sh (unchged)
PRIMECAP Management 10,559,240 sh (-1.23%)
Joel Greenblatt 72,552 sh (-52.04%)
Paul Tudor Jones 20,400 sh (-63.83%)
Jim Simons 198,280 sh (-74.22%)
» More
Q3 2014

AFFX Guru Trades in Q3 2014

Jim Simons 576,885 sh (+190.94%)
Paul Tudor Jones 29,500 sh (+44.61%)
Chuck Royce 90,000 sh (unchged)
PRIMECAP Management 10,559,240 sh (unchged)
Murray Stahl 104,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q4 2014

AFFX Guru Trades in Q4 2014

Joel Greenblatt 38,181 sh (New)
Paul Tudor Jones 30,745 sh (+4.22%)
PRIMECAP Management 10,940,040 sh (+3.61%)
Murray Stahl 104,000 sh (unchged)
Jim Simons 282,620 sh (-51.01%)
Chuck Royce 4,000 sh (-95.56%)
» More
» Details

Insider Trades

Latest Guru Trades with AFFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 83.20
AFFX's P/E(ttm) is ranked higher than
55% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 83.20 )
AFFX' s 10-Year P/E(ttm) Range
Min: 11.36   Max: 971
Current: 83.2

11.36
971
Forward P/E 32.26
AFFX's Forward P/E is ranked higher than
76% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 32.26 )
N/A
PE(NRI) 83.20
AFFX's PE(NRI) is ranked lower than
52% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 83.20 )
AFFX' s 10-Year PE(NRI) Range
Min: 11.71   Max: 971
Current: 83.2

11.71
971
P/B 3.26
AFFX's P/B is ranked higher than
70% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. AFFX: 3.26 )
AFFX' s 10-Year P/B Range
Min: 0.24   Max: 11.78
Current: 3.26

0.24
11.78
P/S 2.63
AFFX's P/S is ranked higher than
71% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.51 vs. AFFX: 2.63 )
AFFX' s 10-Year P/S Range
Min: 0.38   Max: 11.22
Current: 2.63

0.38
11.22
PFCF 29.71
AFFX's PFCF is ranked higher than
87% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 29.71 )
AFFX' s 10-Year PFCF Range
Min: 1.89   Max: 1220.5
Current: 29.71

1.89
1220.5
POCF 23.55
AFFX's POCF is ranked higher than
86% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 23.55 )
AFFX' s 10-Year POCF Range
Min: 1.64   Max: 2657
Current: 23.55

1.64
2657
EV-to-EBIT 55.64
AFFX's EV-to-EBIT is ranked higher than
75% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. AFFX: 55.64 )
AFFX' s 10-Year EV-to-EBIT Range
Min: -2863   Max: 670
Current: 55.64

-2863
670
Current Ratio 3.92
AFFX's Current Ratio is ranked higher than
73% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. AFFX: 3.92 )
AFFX' s 10-Year Current Ratio Range
Min: 1.52   Max: 23.52
Current: 3.92

1.52
23.52
Quick Ratio 3.01
AFFX's Quick Ratio is ranked higher than
70% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. AFFX: 3.01 )
AFFX' s 10-Year Quick Ratio Range
Min: 1.25   Max: 23.21
Current: 3.01

1.25
23.21
Days Inventory 137.36
AFFX's Days Inventory is ranked higher than
69% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 141.40 vs. AFFX: 137.36 )
AFFX' s 10-Year Days Inventory Range
Min: 77.31   Max: 586.61
Current: 137.36

77.31
586.61
Days Sales Outstanding 49.93
AFFX's Days Sales Outstanding is ranked higher than
86% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 84.80 vs. AFFX: 49.93 )
AFFX' s 10-Year Days Sales Outstanding Range
Min: 49.04   Max: 114.29
Current: 49.93

49.04
114.29

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.50
AFFX's Price/Tangible Book is ranked lower than
51% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.30 vs. AFFX: 19.50 )
AFFX' s 10-Year Price/Tangible Book Range
Min: 0.87   Max: 75.92
Current: 19.5

0.87
75.92
Earnings Yield (Greenblatt) 1.80
AFFX's Earnings Yield (Greenblatt) is ranked higher than
66% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. AFFX: 1.80 )
AFFX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 387
Current: 1.8

0.1
387
Forward Rate of Return (Yacktman) -7.85
AFFX's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.26 vs. AFFX: -7.85 )
AFFX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.7   Max: 12.2
Current: -7.85

-19.7
12.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AFF.Germany,
Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.
» More Articles for AFFX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: PXLW, NGPC, MS, CHMT, AFFX Aug 15 2011 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 5,000 Shares Nov 19 2010 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 10,000 Shares Aug 24 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Jul 31 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Solarwinds Inc., PDL BioPharma, Autobytel Inc., Affymetrix May 08 2010 
Affymetrix Inc. Reports Operating Results (10-Q) May 06 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Affymetrix, Richardson Electronics, First Defiance Financi May 02 2010 
Affymetrix Reports Fourth Quarter and Fiscal Year 2008 Results Jan 28 2009 
Affymetrix to Host Conference Call on January 28, 2009 to Announce Fourth Quarter and Fiscal 2008 Re Jan 27 2009 
Weekly CEO Buys Highlight: ScheringPlough Corp., Novellus Systems Inc., SeaBright Insurance Holdings May 01 2008 

More From Other Websites
10-Q for Affymetrix, Inc. May 03 2015
AFFYMETRIX INC Files SEC form 10-Q, Quarterly Report Apr 30 2015
Affymetrix Q1 Earnings, Revenues Top Estimates; Shares Up - Analyst Blog Apr 30 2015
Affymetrix Inc Earnings Call scheduled for 5:00 pm ET today Apr 29 2015
Affymetrix tops Street 1Q forecasts Apr 29 2015
Affymetrix tops Street 1Q forecasts Apr 29 2015
Affymetrix Reports First Quarter 2015 Operating Results Apr 29 2015
AFFYMETRIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 29 2015
Affymetrix Reports First Quarter 2015 Operating Results Apr 29 2015
Q1 2015 Affymetrix Inc Earnings Release - After Market Close Apr 29 2015
Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog Apr 17 2015
BioDelivery Sciences (BDSI) Worth Watching: Stock Up 7.2% - Tale of the Tape Apr 17 2015
AVEO Pharmaceuticals (AVEO) Jumps: Stock Moves Up 16.2% - Tale of the Tape Apr 17 2015
VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog Apr 16 2015
Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog Apr 16 2015
Celsion Gains on Impressive Breast Cancer Study Data - Analyst Blog Apr 16 2015
Clovis Oncology (CLVS) in Focus: Stock Rises 7.5% - Tale of the Tape Apr 16 2015
Celsion (CLSN) Shows Strength: Stock Adds 18.6% in Session - Tale of the Tape Apr 16 2015
Biogen Reports New Data from Acute Optic Neuritis Study - Analyst Blog Apr 15 2015
MiMedx (MDXG) in Focus: Stock Falls 6.2% - Tale of the Tape Apr 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK